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Background: Based on its mechanism of action, PARP inhibitor therapy is expected to benefit mainly tumor cases with
homologous recombination deficiency (HRD). Therefore, identification of tumor types with increased HRD is important for the
optimal use of this class of therapeutic agents. HRD levels can be estimated using various mutational signatures from next
generation sequencing data and we used this approach to determine whether breast cancer brain metastases show altered
levels of HRD scores relative to their corresponding primary tumor.
Patients and methods: We used a previously published next generation sequencing dataset of 21 matched primary breast
cancer/brain metastasis pairs to derive the various mutational signatures/HRD scores strongly associated with HRD. We also
carried out the myChoice HRD analysis on an independent cohort of 17 breast cancer patients with matched primary/brain
metastasis pairs.
Results: All of the mutational signatures indicative of HRD showed a significant increase in the brain metastases relative to their
matched primary tumor in the previously published whole exome sequencing dataset. In the independent validation cohort,
the myChoice HRD assay showed an increased level in 87.5% of the brain metastases relative to the primary tumor, with 56% of
brain metastases being HRD positive according to the myChoice criteria.
Conclusions: The consistent observation that brain metastases of breast cancer tend to have higher HRD measures may
raise the possibility that brain metastases may be more sensitive to PARP inhibitor treatment. This observation warrants
further investigation to assess whether this increase is common to other metastatic sites as well, and whether clinical
trials should adjust their strategy in the application of HRD measures for the prioritization of patients for PARP inhibitor
therapy.
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Introduction
The benefit of improved survival in patients with metastatic
breast cancer is mitigated by the fact that 15%–20% of such
patients will develop brain metastases [1]. In fact, probably due
to longer survival, the incidence of brain metastasis, which is usu-
ally associated with poor prognosis and severe neurological
impairments [2], is rising in breast cancer [1]. Due to its unique
location, and perhaps its distinct biology, treatment options have
been limited.
Homologous recombination (HR) is an error-free mechanism
of double-stranded DNA breaks repair, which is often deficient in
breast and ovarian cancer, sensitizing them to PARP inhibitor
therapy [3, 4]. Currently three PARP inhibitors (olaparib, nira-
parib and rucaparib) have been approved by the Food and Drug
Administration for the treatment of ovarian cancer, and olaparib
has also been approved for the treatment of germline BRCA-
mutated HER2– metastatic breast cancer.
These promising clinical results raise the question whether a
similar clinical benefit can be achieved with PARP inhibitors in
the case of brain metastases as well.
To achieve such therapeutic benefit at least two criteria need to
be satisfied. First, crossing the blood–brain barrier, which was
shown for both niraparib [5] and veliparib [6], making those po-
tential candidates for the treatment of brain metastases.
Secondly, the brain metastases should present HR deficiency to
be sensitive to this type of treatment.
Over the past decade, various studies have analyzed human
cancer genomes for fingerprints left by homologous recombin-
ation deficiency (HRD), and identified predictors to estimate a
tumor’s response to HRD-specific therapy.
The three earliest predictors: HRD-loss of heterozygosity
(HRD-LOH), large-scale state transitions (LST) and the number
of telomeric allelic imbalances (ntAI), commonly known as the
“genomic scar scores,” are based on the investigated tumors’
copy-number profiles and each of them quantifies a different as-
pect of the increased genomic instability linked to HRD [7–9].
Although all of these scars have the tendency to increase in HRD
cases, as of today, none of them has an accepted threshold indi-
vidually to separate HRDþ from HRD– cases. These methods
were later adapted by Myriad Genetics and they are currently part
of the myChoice HRD test [10].
Next generation sequencing allowed the identification of the
mutational signatures of somatic processes [11]. Analysis of the
mutational spectra of nucleotide triplets in tumor specimens
found that a signature characterized by a flat mutational spec-
trum (Signature 3) was connected to HRD; thus, the relative con-
tribution of the corresponding mutational process might be used
as an estimator for the deficiency. The relative proportion of dele-
tions caused by microhomology-mediated end joining can also
be used as a robust estimator for HRD [12]. All these mutational
signatures together with the so-called rearrangement signatures
were combined into a robust logistic-regression model, called
HRDetect [13].
It is important to emphasize that the phenotypes of the samples
(i.e. HR-deficient or HR-proficient) on which all of these estima-
tors relied on were determined from the genotypes of the BRCA1
and BRCA2 genes. Hence, determining the HR-status in a
BRCA1/2 wild-type background remains a challenging task.
So far, it has not been determined how often breast cancer
brain metastases show HR deficiency. We calculated HR defi-
ciency measures in a published next generation sequencing data
of primary breast cancer/brain metastasis pairs (hereinafter
referred to as Brastianos et al. [14] cohort), followed by the
myChoice HRD test in an independent cohort (validation
cohort).
Materials and methods
Brastianos et al. cohort
The whole exome sequencing (WES) data of the Brastianos et al. cohort
were downloaded from the database of Genotypes and Phenotypes,
under accession number phs000730.v1.p1 [14]. The dataset contains bin-
ary alignment files of primary tumors and their corresponding metastatic
pairs for 21 breast cancer cases with all primary tumors having at least
one matched intracranial metastasis. This breast cancer cohort formed
the basis of our initial investigations.
Independent validation cohort
We collected FFPE tissues from 17 cases with primary breast cancer and
corresponding brain metastases. Permissions to use the archived tissue
have been obtained from the Regional Ethical Committee (No.: 510/
2013, 86/2015) and the study was conducted in accordance with the
Declaration of Helsinki.
Germline and somatic mutation calling
The samples (Brastianos et al.) were preprocessed, aligned to the hg19
reference genome with the Burrows-Wheeler Aligner mem algorithm,
and postprocessed (base-recalibration) by the original authors [14]. We
called somatic substitutions along with short insertions and deletions
with MuTect2, and germline mutations of the BRCA1 and BRCA2 genes
with HaplotypeCaller. Both tools constitute a part of the Genome
Analysis Toolkit (GATK 3.7) [15]. The majority of the samples were
derived from formalin fixed, paraffin embedded (FFPE) specimens,
which are well known to contain mutational biases (mostly C>T/G>A
transitions) [16]. We used an approach analogous to the OxoG filter [17]
to remove mutations that were consistent with this FFPE-bias (supple-
mentary Figures S1–S4 and Tables S5–S7, available at Annals of Oncology
online).
Genotypic background. As it was reported earlier [14], none of the
Brastianos et al. samples had somatic mutations in either BRCA1 or
BRCA2; however, four blood-derived normal samples showed deleteri-
ous germline mutations being present in at least one of the genes (supple-
mentary Figure S7 and Table S8, available at Annals of Oncology online).
Classification of deletions
Deletions were grouped into three classes (supplementary Figure S5 and
S6, available at Annals of Oncology online): (i) if the entire deleted se-
quence of a single event was repeated after the breakpoint, it was consid-
ered a repeat, (ii) if only the first n nucleotides were repeated after the
breakpoint, it was considered a size n microhomology and (iii) if it had
no such characteristics, it was treated as a unique deletion. In order to
eliminate those microhomologies that have appeared by pure chance in-
stead as the result of the activity of the microhomology-mediated end
joining DNA-repair pathway, they had been further divided into n< 3
and n 3 subgroups. In our prediction models only the n 3 subgroup
was considered.
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Copy number analysis and genomic scar scores
Deriving copy number data from the Brastianos et al. whole exome
sequences was executed using the sequenza R package [18]. The ranges of
ploidy and cellularity were confined into the [1, 5] and [0.1, 1] intervals,
respectively, and segmentation data were generated for autosomes only.
The three genomic scar scores were calculated using their standard defini-
tions (supplementary Figures S9–S12 and Table S1, available at Annals of
Oncology online).
The WES-HRDetect model
The original HRDetect model [13] was trained on mutational features
derived from 560 breast cancer whole genome sequences, and although
the authors have created an artificial whole exome variant (limiting WGS
to typical WES genomic coverage area), the exact details of this computa-
tional pipeline were not published. Therefore, in order to use this predict-
or for our WES samples, we had to retrain the LASSO logistic regression
model on the 560 artificial WES dataset, with the HRD-LOH scar scores
included [13] (supplementary Figures S18–S21 and Tables S4 and S11,
available at Annals of Oncology online).
myChoice HRD analysis
DNA was extracted from FFPE tissue sections and analysis carried out as
previously described by Myriad Genetics [10]. Briefly, genome-wide SNP
data and sequence spanning the coding regions of 111 genes were gener-
ated using a custom hybridization panel [10]. Allelic imbalance profiles
were generated to determine the scores for the three genomic scars (ntAI,
HRD-LOH and LST). The combined HRD score was derived from these
three independent genomic scars. A myChoice HRD threshold of 42 has
previously been developed to identify HR-deficient tumors using this test
[10]. Tumors are considered HRDþ if they have a high myChoice HRD
score (42) or a tumor BRCA1/2 mutation and HRD– if they have a low
myChoice HRD score (<42) and wild-type BRCA1/2.
Results
Genomic scars–based HRD measures
We determined the three genomic scar scores (HRD-LOH, LST
and ntAI) in the Brastianos et al. dataset. All three WES-based
scores, and their sum, had significantly increased in brain meta-
stases (P 0.01 for all the three measures and for their sum;
Figure 1, supplementary Figures S13 and S14 and Tables S9 and
S10, available at Annals of Oncology online), regardless of the mu-
tational backgrounds of the samples. We also compared the scar
scores of patients who received brain radiation treatment before
the resection of their brain metastasis (5 of 21) to the scores of
those patients who did not and found no significant difference
between the two groups (supplementary Figures S15 and S16,
available at Annals of Oncology online), suggesting that brain ir-
radiation did not introduce bias into our analysis.
To independently validate these observations, we have
assembled a cohort of primary breast cancer brain metastasis
pairs, which were processed and assessed for the myChoice HRD
score as described in [10]. Two of 17 of these patients (patients 1
and 12; Figure 2A and supplementary Tables S2 and S3, available
at Annals of Oncology online) had biallelic BRCA1 mutations (a
deleterious somatic deletion and LOH in both cases), and two
showed signs of monoallelic BRCA2 mutations (4 and 5); how-
ever, the latter two mutations’ clinical significance could not be
determined. In one case (patient 7), the HRD score of the primary
tumor could not be determined.
Figure 2B shows that in 14 of 16 cases the brain metastasis had
a higher myChoice HRD score than the primary tumor. In four
cases, the brain metastasis “switched myChoice HRD status” rela-
tive to the primary tumor from a low myChoice HRD score
(HRD–) to a high myChoice HRD score (HRDþ), based on the
currently accepted threshold value of 42 [10]. One of these
donors’ (patient 3) metastasis, however, was likely to be derived
from a HRDþ recurrent tumor that was diagnosed 4 years after
the appearance of the initial tumor. The remaining three patients
had estrogen receptor positive (ERþ) primary tumors and meta-
stases, which means that 38% of the ERþ patients’ metastases in
our validation cohort had switched HRD status. In a single case
(patient 6), the metastatic sample turned out to be HRD–, while
its primary counterpart was HRDþ.
As expected, the myChoice HRD scores of the two BRCA1
mutants were larger than 42, i.e. both of these samples were
HRDþ. The statistical comparison of the myChoice HRD scores
yielded a significant difference between the primary and meta-
static groups (Figure 2B), with a P-value of 5.4E–6, supporting
our findings on the Brastianos et al. dataset.
We also found a significant correlation between the changes in
the scar scores and the time elapsing between the detection of the
primary tumor and the brain metastasis (rBrastianos¼ 0.52,
rcontol¼ 0.54) in the case of both cohorts (supplementary Figures
S17 and S23, available at Annals of Oncology online).
Somatic point-mutation signatures in the
Brastianos et al. cohort
As a result of our signature extraction process, 3 of 21 primary
samples (149, 244 and 296) and 1 of 27 metastatic samples (296)
failed to pass the reconstruction step, hence their somatic signa-
ture composition could not be determined (supplementary
Figure S8, available at Annals of Oncology online). The rest of the
signature compositions are summarized in Figure 3A.
We found that the primary breast tumor mutational profiles
were dominated by signature 1 (aging-related signature), with
lesser contributions from signature 2 (APOBEC signature), sig-
nature 3 (BRCA mutation associated), signatures 5 and 6.
Strikingly, signature 3, the BRCA mutation–associated signature
increased in 13 of 18 patients’ brain metastases. Interestingly, in
about 20%–25% of the brain metastasis cases, signature 5 (an-
other aging-related signature) has become similarly dominant as
signature 1. Finally, in a single case (302), signature 17 (unknown
relevance and biological origin) became the predominant muta-
tional signature in the metastasis.
Analysis of deletions
Since the Brastianos dataset was whole-exome sequenced, the
number of high fidelity deletions in the samples was low
(7.336 1.44 in primary tumors and 9.366 1.49 in metastases),
and although the contribution of microhomology-mediated
deletions increased in the metastases (supplementary material
subsection 2.3.3, available at Annals of Oncology online), the dif-
ference between the two groups was not significant (P¼ 0.13).
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WES-HRDetect scores
The original HRDetect model, developed using WGS data, is not
directly applicable to WES data. Since the Brastianos et al. dataset
contained only WES data, we extracted the features of HRDetect
that could be calculated based on the available sequences (HRD-
LOH, substitution signatures, and deletion classes) and retrained
the LASSO regularized logistic regression model on them. Using
the same principles as the original publication [13], we developed
a similar complex measure of HR deficiency using WES data.
(For details, see supplementary material section 4, available at
Annals of Oncology online.)
This WES-HRDetect model also distinguished well between
HR-deficient and HR-proficient primary breast cancers, as deter-
mined by e.g. BRCA mutation status (supplementary material
section 4, available at Annals of Oncology online). Therefore, we
calculated the WES-HRDetect scores for the primary breast can-
cer brain metastasis pairs as well. Compared with the results
obtained by the genomic scar scores, this new measure showed an
even more substantial increase of HR-deficiency in brain meta-
stases relative to the primary tumors (Figure 3B,C and supple-
mentary Figure S22, available at Annals of Oncology online). The
distribution of these predictor scores was not affected by either
the BRCA1/2 germline genotypes of the samples, or the brain ra-
diation history of the patients.
The distribution of the breast cancer brain metastatic WES-
HRDetect scores was compared with the distribution of the same
model ran on the original 560 breast cancer exomes. We found a
significant difference between the two cohorts (Figure 3D) sug-
gesting that there were significantly more tumors in the
Brastianos et al. brain metastasis cohort with high (0) WES-
HRDetect scores than in the pure primary cohort of breast can-
cers. By using the score 0.7 threshold that was determined for
the original model, we concluded that four patients’ metastases
changed HRD status from HRD– to HRDþ, among which two
had germline mutations in at least one of the BRCA1/2 genes.
One of the BRCA1 germline patient’s (222), however, went
through an opposite change; while the primary sample was
HRDþ, the metastasis was HRD–.
Discussion
This work is the first demonstrating that the various DNA aberra-
tion-based HRD measures are significantly higher in brain meta-
stases relative to their primary breast tumor counterparts. The
possibility of such an increase was previously suggested in a pub-
lication showing that a BRCA1 deficient-like gene expression sig-
nature is higher in breast cancer brain metastases, but that
study did not use patient-matched primary metastasis sample
pairs [19].
This discrepancy has several clinical consequences. Ideally, only
patients sensitive to a given therapy should receive that particular
treatment. In the case of PARP inhibitors, it is likely that mainly
patients with HR deficiency benefit from this form of therapy.
Therefore, correlating the clinical benefit of PARP inhibitor ther-
apy with HR status of the tumors has been intensely investigated
[3]. However, HR status is often determined in biopsies derived
from the primary tumor but clinical benefit is determined at a
more advanced, often metastatic stage of the disease. If the HR de-
ficiency status is significantly different in the metastases relative to
the primary tumors then the observed correlations will be cor-
rupted leading to contradictory clinical results. For example, in
the case of breast cancer repeated observations demonstrated a
correlation between the ntAI score and response to platinum-
based therapy [7]. The TNT trial [20], however, studied the effi-
cacy of platinum-based therapy in locally advanced or metastatic
triple-negative breast cancer and failed to find a correlation be-
tween the myChoice HRD score and response to carboplatin. It
should be noted, however, that the myChoice HRD score was
determined on the primary tumors and not on the metastases.
The discrepancy between the myChoice HRD score of the primary
and metastatic sites presented in this study may be partially re-
sponsible for this lack of correlation.
There are several ongoing clinical trials evaluating the potential
clinical benefit of PARP inhibitor treatment in metastatic breast can-
cer, including NCT02723864 (https://clinicaltrials.gov/ct2/show/
NCT02723864). This trial, however, excludes patients with active
brain metastasis. Based on our results, it seems likely that breast can-
cer brain metastases might be a particularly sensitive population.
Figure 1. Genomic scar scores of the Brastianos et al. breast cancer brain metastasis samples. Distributions of the homologous recombin-
ation deﬁciency–loss of heterozygosity (HRD-LOH) (A), large-scale state transitions (LST) (B) and number of telomeric allelic imbalances (ntAI)
(C) scores. The corresponding primary-metastatic pairs are connected by thin lines. Scores for each of these measures were increased in
metastases compared with primary tumors with P-values of the paired t-tests: pLOH¼ 1.98E–6, pLST¼ 7.3E–6 and pntAI¼ 7.31E–5, respect-
ively. The brain radiation history and the germline status of the BRCA1/2 genes are encoded by different shapes and colors, respectively.
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The SWOG trial S1416 is a Phase II Randomized Placebo-
Controlled Trial of Cisplatin with or without ABT-888 (Veliparib)
in Metastatic Triple-Negative Breast Cancer (TNBC) and/or BRCA
Mutation-Associated Breast Cancer. This trial includes patients with
brain metastasis but excludes patients with estrogen receptor posi-
tive breast cancer. As we showed in our validation cohort, the major-
ity of estrogen receptor positive breast cancer brain metastasis cases
showed high myChoice HRD scores. It might be worth establishing
the proportion of HRDþ ERþ breast cancer cases on a larger cohort
as those patients might be responding to PARP inhibitors as well.
The significant increase in HR deficiency scores in brain metasta-
ses may arise due to at least two distinct mechanisms. (i) Clonal se-
lection of tumor cells with higher HR deficiency score. Tumors cells
with higher levels of genomic instability, higher levels of HR defi-
ciency may be able to adjust more readily to a distinct environment
such as the brain. (ii) It is also possible that the growing brain
metastases become gradually more genomically unstable due to
some unidentified mechanism. Both mechanisms are consistent
with the fact that the time elapsing between primary tumors and
brain metastases often takes up to 5–10 years in breast cancer, and
the length of this time showed a strong correlation with the increase
in the various HRD measures in brain metastases.
Brain metastases of breast cancer patients are surgically removed
with palliative intent in a significant number of cases. According to
the guidelines, surgical resection is recommended in patients with a
limited number (1–3) of newly diagnosed brain metastases, especial-
ly with controlled systemic disease and good performance status
[21]. In such cases, when the histological material is already avail-
able, it might be worth considering determining the HR deficiency
score in order to determine the likely sensitivity of the tumor to
PARP inhibitors versus other second-/third-line therapeutic
options.
Figure 2. Summary of the analysis carried out on the validation cohort by Myriad Genetics. (A) Hormone receptor and HER-2 status along
with the mutational proﬁle and HRD status of the control samples determined by Myriad Genetics. In the sample, names P stands for primary
and M stands for metastasis. In the majority of cases (14 of 16), the HRD score was higher in the metastasis compared with the primary
tumor. In four cases, three of which were ER positive, the HRD status of the metastasis switched to positive from an HRD negative primary.
Patients 4 and 5 had uncertainly signiﬁcant BRCA2 monoallelic mutations. Mutations of either PTEN, RIF1 or TP53 were gained in ﬁve of the
brain metastases. LOH was more common in the brain metastases. (B) Genomic scar scores determined by Myriad Genetics summed to-
gether into a single HRD score. HRD scores were increased in metastases compared with primary tumors (P¼ 5.4E–6). The ﬁgure is divided
into four quadrants by the HRD score¼ 42 lines, among which the top left quadrant contains those four cases, whose HRD status changed
from HRD– to HRDþ. Two of these samples (marked with asterisks) belong to the same patient (patient 2).
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Figure 3. Somatic signature composition and WES-HRDetect scores of the Brastianos et al. samples. (A) Summary of somatic point muta-
tions. The ﬁgure can be divided into three panels. The top panel contains the total number of point mutations in the samples, colored by
the relative abundance of the six mutational directions. The middle panel shows the somatic point-mutation signature compositions of the
triplet mutational spectra. The reconstruction errors (supplementary material section 3, available at Annals of Oncology online) of specimens
0149-P, 0244-P, 0296-P and 0296-MT did not pass the cosine similarity threshold, hence those samples have no colors on their bars in the
plot. The bottom panel of the ﬁgure indicates the germline genotype of the BRCA1/2 genes in the normal sample, and the brain radiation
history of the patient. (B) WES-HRDetect scores of the primary and metastatic samples. The germline genotypes of the BRCA1/2 genes and
brain radiation history of the patient is also presented below the bars. The red dashed line indicates the score 0.7 threshold, determined by
the original creators of the HRDetect model. (C) Primary WES-HRDetect scores versus metastatic WES-HRDetect scores. Noticeably, there is
only a single case (PB0222) for which the primary sample’s score is signiﬁcantly higher than its metastatic pairs. The difference between the
two groups was tested with a paired Wilcoxon signed rank test: P¼ 1.64E–6. (D) Black and gray curves; cumulative distributions of the origin-
al HRDetect model’s scores ran on the 560 WGS and WES. Red and blue curves: cumulative distributions of the WES-HRDetect model’s scores
ran on the 560 breast cancer whole exomes and on the Brastianos et al. breast cancer dataset. The latter two distributions were compared
with each other by a Kolmogorov–Smirnov test, the D statistic and P-value of which is indicated on the plot.
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